Origimm Biotechnology

Origimm Biotechnology is an Austrian biotechnology company focused on the discovery of antigens and the development of novel vaccines for skin diseases. The company leverages its proprietary ProX platform to identify protective surface proteins from the skin microbiome, specifically targeting inflammatory conditions like acne vulgaris. Its lead candidate, ORI-001, is a therapeutic vaccine based on recombinant proteins that entered Phase 1 clinical trials to treat acne. In December 2021, Origimm was acquired by Sanofi, integrating its expertise in skin microbiome-derived biologics into Sanofi's global vaccine portfolio. The acquisition allows Sanofi to explore the potential of immunotherapy in dermatology and expand its research into the skin microbiome.